Startseite>>Signaling Pathways>> JAK/STAT Signaling>> EGFR>>AC480 (BMS-599626)

AC480 (BMS-599626) (Synonyms: BMS-599626)

Katalog-Nr.GC13257

AC480 (BMS-599626) (AC480) ist ein selektiver und oral bioverfÜgbarer HER1- und HER2-Inhibitor mit IC50-Werten von 20 bzw. 30 nM. AC480 (BMS-599626) zeigt ~8-mal weniger potent gegenÜber HER4 (IC50=190 nM), >100-mal weniger potent gegenÜber VEGFR2, c-Kit, Lck, MEK. AC480 (BMS-599626) hemmt die Tumorzellproliferation und hat das Potenzial, das Ansprechen des Tumors auf eine Strahlentherapie zu steigern.

Products are for research use only. Not for human use. We do not sell to patients.

AC480 (BMS-599626) Chemische Struktur

Cas No.: 714971-09-2

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
191,00 $
Auf Lager
5mg
83,00 $
Auf Lager
25mg
278,00 $
Auf Lager
100mg
549,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

AC480 (BMS-599626) is a potent, selective inhibitor of human epidermal growth factor receptor (HER) that inhibits HER1 and HER2 with IC values of 20 nM and 30 nM, respectively. AC480 has been proved to inhibit HER1 in an ATP-competitive manner. On the contrary, AC480 has shown to be an ATP noncompetitive inhibitor of HER2 [1]

AC480 inhibited the proliferation of Sal2 cells derived from a transgenic mouse tumor, breast tumor and gastric carcinoma cell lines, GEO colon tumor cells, non–small-cell lung tumor cells line via HER1 and/or HER2 signalings [1].

AC480 by oral administration has been demonstrated to suppress the growth of Sal2 tumor, GEO xenograft tumor, KPL-4 and BT474 breast tumors, N87 gastric tumor, A549 and L2987 non–small-cell lung tumors in nude mice [1].

References:
[1] Wong TW1, Lee FY, Yu C, Luo FR, Oppenheimer S, Zhang H, Smykla RA, Mastalerz H, Fink BE, Hunt JT,Gavai AV, Vite GD. Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6186-93.

Bewertungen

Review for AC480 (BMS-599626)

Average Rating: 5 ★★★★★ (Based on Reviews and 35 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for AC480 (BMS-599626)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.